Nexalin technology announces ucsd irb approval for use of halo™ clarity in clinical trials for mtbi and ptsd treatment

Houston, tx, feb. 18, 2025 (globe newswire) -- nexalin technology, inc. (nasdaq: nxl; nxliw) (the “company” or “nexalin”) the leader in deep intracranial frequency stimulation (difs™) of the brain, announces that it has received institutional review board (irb) approval from the university of california, san diego (ucsd) for clinical testing of its halo™ clarity (halo) headset in human subjects. this study is being conducted independently by ucsd.
NXL Ratings Summary
NXL Quant Ranking